ArticleCommunications medicine2025
Molecular profiles of the great obstetrical syndromes reveal common features and dynamic changes in early pregnancy.
Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe great obstetrical syndromes (GOS) encompass a spectrum of pregnancy-related complications that are the major determinants of maternal and neonatal mortality. Although shared placental pathology underlies these complications, knowledge of the molecular commonalities before clinical presentation remains incomplete.
methodsIn this case-control study nested within the prospective Shanghai Birth Cohort, we investigated the molecular characteristics underlying GOS conditions in the pre-symptomatic phase using serum samples from 203 nulliparas who subsequently developed GOS and 181 controls. A multi-omics approach combining protein, metabolite, and gene analysis was employed.
resultsHere we show a shared molecular background of the spectrum of all tested GOS conditions at the co-expression module, molecule, pathway, multi-omics network and genome levels. In early pregnancy, one protein module mainly involved in the immune system and platelet function shows significant associations across the spectrum of tested GOS conditions. Different conditions share several hub proteins and enriched pathways in the innate immune system and platelet activation, signaling and aggregation. Common molecular changes could be observed before 14 weeks of gestation. Different groups of hub proteins demonstrate the potential to differentiate between normal and complicated pregnancies before and after 14 weeks of gestation.
conclusionsWe highlight the shared molecular signatures among different GOS conditions in the pre-symptomatic phase, suggesting the potential of a common screening and intervention strategy. Our results further support the notion that the prevention of GOS should start at 14 weeks of gestation or earlier, when the molecular signature changes have already emerged.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.